<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090839</url>
  </required_header>
  <id_info>
    <org_study_id>20190760</org_study_id>
    <nct_id>NCT05090839</nct_id>
  </id_info>
  <brief_title>Expressing Personal Recollections in English or Spanish to Alleviate Traumatic Emotions (Exprésate)</brief_title>
  <acronym>Exprésate</acronym>
  <official_title>Expressing Personal Recollections in English or Spanish to Alleviate Traumatic Emotions (Exprésate)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Latino Health Research Opportunities</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test if expressive writing about traumatic events has&#xD;
      positive changes in women living with post-traumatic stress.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PTSD symptoms as assessed by the Impact of Event Scale</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <description>Post Traumatic Stress Disorder (PTSD) symptoms will be assessed via the Impact of Event Scale (IES). IES is a 22-item self-report instrument that corresponds to Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) symptoms of PTSD over last 7 days. The IES has a total score ranging from 0 to 88 with the higher score indicating greater PTSD symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in verbal learning as assessed by Hopkins Verbal Learning Task (HVLT)</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <description>HVLT measures verbal learning and memory function. It is scored based on the total number of words recalled in 3 immediate trials with scores ranging from 0 (no words recalled) to 48 (all 12 words recalled after each of the trials)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in functional connectivity of the Default Mode Network (DMN)</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <description>DMN is a large scale network of interacting brain regions implicated in emotion and memory. Activity/connectivity indexed by Fisher's Z or Beta wt using fMRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in salivary alpha amylase (sAA) levels</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <description>As assessed from saliva samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in salivary adrenal corticotrophin releasing hormone (ACTH) levels</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <description>As assessed from saliva samples</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Post Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Spanish-Only Writing Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will be asked to write about their most traumatic or upsetting experiences for a total of 4 sessions (one session a week for 4 consecutive weeks). The participant will be required to write in Spanish only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>English-Only Writing Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will be asked to write about their most traumatic or upsetting experiences for a total of 4 sessions (one session a week for 4 consecutive weeks). The participant will be required to write in English only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Trauma Daily Event Writing in Spanish Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will be required to write once weekly for 4 consecutive weeks. Participants will be instructed to write objectively about what they did the day prior and to avoid writing about their emotions or opinions. The participant will be required to write in Spanish only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Weekly Emotional Disclosure (WED)</intervention_name>
    <description>Online writing session with each session lasting approximately 30 minutes. Participants will be instructed to write about either a major traumatic life experience or what the participant did the previous day.</description>
    <arm_group_label>English-Only Writing Group</arm_group_label>
    <arm_group_label>Non-Trauma Daily Event Writing in Spanish Group</arm_group_label>
    <arm_group_label>Spanish-Only Writing Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 21 years&#xD;
&#xD;
          2. Elevated PTSD symptoms as assessed by the Post-Traumatic Stress Disorder Checklist&#xD;
             Scale-Version DSM 5 (PCL-5) using a cut-off of 34 or above&#xD;
&#xD;
          3. On a stable anti-retroviral therapy regimen for &gt; 6 months as assessed with the Adult&#xD;
             AIDS Clinical Trial Group structured interview&#xD;
&#xD;
          4. Spanish-English bilingual as measured by the Brief Acculturation Scale for Hispanics&#xD;
             (cut-off of 3), Spanish speaker or English speaker&#xD;
&#xD;
          5. Participant is willing and able to sign Informed Consent Form (ICF)&#xD;
&#xD;
          6. self-report as Latina&#xD;
&#xD;
          7. HIV positive serostatus as determined by medical record within the last 12 months&#xD;
&#xD;
          8. Born female.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Left-handedness or ambidextrous&#xD;
&#xD;
          2. Inability to tolerate the scanning procedures&#xD;
&#xD;
          3. Metal in body or prior history working with metal fragments&#xD;
&#xD;
          4. Any other contraindications for MRI examination (e.g., metallic implants such as&#xD;
             pacemakers, surgical aneurysm clips, or known metal fragments embedded in the body)&#xD;
&#xD;
          5. currently pregnant or could be pregnant&#xD;
&#xD;
          6. Heavy alcohol intake (&gt; 3 drinks) within 12 hours prior to participation in Functional&#xD;
             Magnetic Resonance Imaging (fMRI)&#xD;
&#xD;
          7. Evidence from health history of neurological or systemic disorder which can cause&#xD;
             cognitive impairment&#xD;
&#xD;
          8. Self-reported current diagnosis of psychiatric disorder or psychoactive substance&#xD;
             abuse or dependence&#xD;
&#xD;
          9. Recent history (within two years) of myocardial infarction&#xD;
&#xD;
         10. Severe cardiovascular disease, or currently active cardiovascular disease (e.g.,&#xD;
             angina, cardiomyopathy)&#xD;
&#xD;
         11. Uncontrolled hypertension or hypotension&#xD;
&#xD;
         12. History of closed trauma with loss of consciousness&#xD;
&#xD;
         13. Space occupying lesions (e.g., mass lesions, tumors)&#xD;
&#xD;
         14. Central Nervous System (CNS) infection&#xD;
&#xD;
         15. CNS vasculitis&#xD;
&#xD;
         16. CNS demyelinating disease (e.g., multiple sclerosis)&#xD;
&#xD;
         17. Congenital CNS abnormality (e.g., cerebral palsy)&#xD;
&#xD;
         18. Seizure disorders&#xD;
&#xD;
         19. History of cerebrovascular disease (e.g., stroke, TIA's)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger McIntosh</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roger McIntosh</last_name>
    <phone>305-243-2047</phone>
    <email>r.mcintosh@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger McIntosh</last_name>
      <phone>305-243-2047</phone>
      <email>r.mcintosh@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Roger McIntosh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Roger McIntosh</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

